NEW YORK, NY / ACCESSWIRE / September 19, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Mallinckrodt Public Limited Company (MNK)
Class Period: February 28, 2018 to July 16, 2019
Lead Plaintiff Deadline: September 24, 2019
The lawsuit alleges Mallinckrodt Public Limited Company made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in MNK: http://www.kleinstocklaw.com/pslra-1/mallinckrodt-public-limited-company-loss-submission-form?id=3601&from=1
Valaris plc (VAL)
Class Period: April 11, 2019 to July 31, 2019
Lead Plaintiff Deadline: October 21, 2019
The lawsuit alleges that throughout the class period, Valaris plc made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (ii) the foregoing was reasonably likely to have a material negative impact on the Company's second quarter 2019 results; (iii) the merger leading to Valaris's establishment could not deliver on its touted benefits; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in VAL: http://www.kleinstocklaw.com/pslra-1/valaris-plc-loss-submission-form?id=3601&from=1
Sarepta Therapeutics, Inc. (SRPT)
Class Period: September 6, 2017 to August 19, 2019
Lead Plaintiff Deadline: October 29, 2019
According to the complaint, Sarepta Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in SRPT: http://www.kleinstocklaw.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?id=3601&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: